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ABSTRACT:  
Chemotherapeutic agents administered intravesically to treat bladder cancer have limited efficacy 
due to periodic dilution and wash-out during urine formation and elimination.  This review describes 
the pathophysiology, prevalence and staging of bladder cancer, and discusses several formulation 
strategies used to improve drug residence within the bladder.  These include the use of amphiphilic 
copolymers, mucoadhesive formulations, hydrogels, floating systems, and liposomes.  Various in 
vitro and in vivo models recently employed for intravesical drug delivery studies are discussed. Some 
of the challenges that have prevented the clinical use of some promising formulations are identified.  
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1 Introduction 
Bladder cancer (BC) is the most predominant malignancy affecting the urinary tract, characterised by 
proliferation of abnormal cells in the urothelial lining of the urinary bladder. It is commonly divided 
into non-muscle invasive bladder cancer (NMIBC) which makes up 80% of cases at presentation and 
muscle invasive bladder cancer (MIBC) where the cancer extends into the underlying smooth 
muscle. The latter makes up 15% of cases at presentation with the remaining 5% presenting with 
metastases (Cheung et al., 2013). Intravesical therapy is only effective in NMIBC and is never used in 
MIBC. Haematuria is the commonest symptom in 85% patients but other clinical presentations may 
include urinary urgency and painful urination (Kaufman et al., 2009). It is ranked 7th and 9th in terms 
of cancer incidence in the United Kingdom (UK) and worldwide, respectively (Cheung et al., 2013; 
Torre et al., 2015) as well as being the fifth based on prevalent cancer types among European men 
(Aziz et al., 2016).  
In 2015 in the UK, 6,169 new BC cases were diagnosed in men versus 2,331 new cases in women 
(Cancer Research, 2017) and it is projected that by 2035 there will be 7,771 BC related deaths per 
year (Cancer Research UK, 2016). BC is statistically twice as prevalent in the white population than in 
the black population; however in terms of mortality (Schinkel et al., 2016), with five-year survival 
rate is considerably higher in the white community (80%) in comparison with the black community 
(64%) (Torre et al., 2015). The greatest risk factor for BC is smoking and the risk is 2 to 6 fold higher 
for smokers than non-smokers, and is responsible for almost 31% and 14% of BC deaths in male and 
female smokers, respectively (Torre et al., 2015). In Africa, 50% of BC patients have a previous 
history of  infection with the water-borne parasite, Schistosoma hematobium, whereas the incidence 
of such BC cases worldwide is only 3% (Sievert et al., 2009). 
Non-muscle invasive bladder cancer (NMIBC), also called superficial BC is the most prevalent form of 
BC at first diagnosis. It progresses to MIBC in about 15% of patients with a poor prognosis despite 
transurethral resection of the bladder tumor  (TURBT) and Bacillus Calmette-Guérin (BCG) 
immunotherapy (Williams et al., 2010) and therefore frequent cystoscopic surveillance of the 
bladder is necessary following initial therapy  (Torre et al., 2015). BC has the highest cost of therapy 
of any cancer over the lifetime of the affected individual due to the associated cost of surveillance 
and treatment (D. A. Barocas et al., 2012; Sievert et al., 2009; Yeung et al., 2014).Therefore, 
improved BC therapeutic delivery systems have been investigated over the last two decades (Figure 
1) in an attempt to reduce the clinical and economic burden of this disease.  
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Figure 1: Number of publications reporting bladder cancer therapeutic delivery systems (1996-
2016), Source: Web of Knowledge (search terms: bladder cancer, delivery systems). 
 
The degradative hepatic enzymes and gastric acid lowers oral bioavailability of BC therapeutic 
formulations while systemic therapy is less efficient due to the poorly vascularised urothelium 
(Elstad and Fowers, 2009; GuhaSarkar and Banerjee, 2010). Increasing systemic drug dose with the 
aim of improving local drug concentration within the bladder leads to elevated adverse drug 
reactions and non-selective toxic effects on healthy tissues (GuhaSarkar and Banerjee, 2010). 
Intravesical Drug Delivery (IDD) (Figure 2) is the instillation of one or multiple therapeutic agents 
through a catheter, directly into the bladder (Zhang et al., 2014). IDD provides site-specific drug 
delivery with minimal toxicity (GuhaSarkar and Banerjee, 2010); and this may help to reduce tumor 
recurrence and progression (van Rhijn et al., 2009) because localised therapy improves therapeutic 
drug concentrations in the bladder which destroys residual urothelial cancerous cells (Kaufman, 
2006; Kaufman et al., 2009; Konety et al., 2007). Due to cellular and physiological limitations posed 
by the urothelium as well as urine, it is not sufficient to simply administer cytotoxic formulations 
intravesically; there is a need for careful design of drug delivery systems that would be able to 
circumvent these barriers. 
Some good reviews have been published that considered varieties of nanoparticles and 
nanotechnology for BC therapy and / or diagnosis (Chen et al., 2015; GuhaSarkar and Banerjee, 
2010; Tomlinson et al., 2015) but some of the nanoparticulate systems discussed were developed 
over a decade ago and recent studies were not discussed fully in some of the articles. Moreover, 
formulation strategies that require adjunct equipment such as electromotive device assisted therapy 
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(EMDA) and hyperthermia (HT)  has not been widely embraced by urologists because of their 
complex delivery modalities (Barocas et al., 2012).  
This review, therefore, will discuss briefly the pathophysiology, prevalence and staging of BC and will 
focus on advanced polymeric formulations investigated for BC management that have not been 
covered previously. Also, in vitro and in vivo models that are currently used for IDD studies will be 
discussed. The reviewed advanced drug carriers are categorised into four groups based on non-
particulate, particulate, composite systems of hydrogels and particles as well as liposomal drug 
carriers. 
2 Bladder Physiology 
2.1 Structure of the bladder 
In order to carry out its urine storage and voiding functions, the bladder (Figure 2) can change 
volume although it remains almost spherical in shape (GuhaSarkar and Banerjee, 2010). The bladder 
wall is comprised of four layers: the urothelium, lamina propria, detrusor muscle, and serous 
(adventitia) layers (Konety et al., 2007). The urothelium acts as a permeability barrier and comprises 
of umbrella cells knitted together by tight junctions and enveloped by uroplakin plaques, mucin, 
intermediate and basal cell layers. These components prevent diffusion of pathogenic and toxic 
substances into the systemic circulation; their detailed functions have been discussed in the previous 
review (GuhaSarkar and Banerjee, 2010). Regulatory information emanating from the bladder lumen 
is transmitted by the urothelium to the surrounding tissues (myofibroblasts and musculature) via 
different neurotransmitters including adenosine triphosphate, adenosine and acetylcholine 
(Khandelwal et al., 2009). The urothelium is covered by a layer of glycosaminoglycans which limits 
the adherence of negatively charged drug carriers (Lewis, 2000). This also means that, systemic 
therapeutic agents for BC treatment cannot diffuse efficiently into the bladder (Soler et al., 2008). 
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Figure 2: Schematic diagram showing various segments of the bladder. This image was designed 
and kindly provided by Ms Stephanie Bull.  
 
2.2 Urine Volume and Composition: 
The volume of urine in a human bladder is dependent on the sex, race and ethnicity of an individual 
but in the adult it averages around 350 - 450 mL when full (Gray, 2012) although the first sensation 
of urination occurs at around  150 to 200 mL of urine (GuhaSarkar and Banerjee, 2010). Urine 
voiding activity is regulated by the myovesical plexus within the bladder wall which produces a 
specific sensation when sufficient urine is present in the bladder and sends a voiding signal to the 
detrusor muscle which relaxes or contracts appropriately in order to regulate the extent and 
frequency of voiding (Khandelwal et al., 2009).  
3 Bladder Cancer  
3.1 Genetic / Molecular expressions in Bladder Cancer 
Some of the genetic materials that are expressed in BC can be used as molecular targets to design 
effective therapies. For example, survivin detectable in the urine of BC patients (Smith et al., 2001) 
has been implicated in BC as it improves the survival rate of cancerous cells by preventing cell death 
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(Swana et al., 1999). BC patients  also are known to express particular mucins (MUC1 and MUC3) 
associated with bladder malignancies  (Cardillo et al., 2000).  
The natural immune system of the bladder is achieved through uroplakins, a group of proteins found 
at the apex of the umbrella cell membrane, namely UPIa, UPIb, UPII, and UPIIIa. They induce 
bacterial death when infected. They also perform barrier functions along with tight junctions, where 
they prevent drug diffusion across the urine / bladder tissue interface (Kong et al., 2004; Wu et al., 
1994; Yu et al., 1994). Changes in the glycosylation of uroplakins especially UPIII may depict 
advanced stages of BC, in addition to clinical conditions such as urinary tract infections and 
interstitial cystitis (Kątnik-Prastowska et al., 2014). 
 Lewis X glycoantygen, sialyl-Tn (carbohydrate) and its degrading enzyme (sialyltransferase) are 
expressed on the urothelium and are markers for BC (Kątnik-Prastowska et al., 2014). Metabolomics 
of urine samples from BC and non-BC subjects’ revealed that biomarkers (lipid-metabolic products) 
such as arachidonite, palmitoyl sphingomyelin, lactate, adenosine and succinate are found in BC 
patients only (Wittmann et al., 2014). Chemokine ligand 1 (CXCL1), which modulates interaction 
between stroma and urothelium, in order to accelerate tumor progression and metastasis, is also 
expressed in urine samples of BC patients (Burnier et al., 2015). 
3.2 Stages of bladder cancer 
About 90% of BC cases are transitional cell carcinomas while squamous cell carcinomas occurs in 3 - 
7% patients and around 2%  have adenocarcinomas (Sharma, 2014). Usually, the urothelial layer of 
the bladder is initially affected by most BC types. The nearby lamina propria and muscular layer 
becomes involved as the tumor progresses. Afterwards, the lymph nodes or pelvic organs are also 
affected (Sharma, 2014). The metastatic stage arises when cancerous cells divide and spread to 
distant organs such as lungs, liver and bone marrow (Sharma, 2014).  
The tumor stage defines the extent of disease progression (Bischoff and Clark, 2009); and the tumor 
node metastasis staging system developed by International Society of Urological Pathology in 1997 
for BC classification is still being used by World Health Organization (WHO) (Moch et al., 2016). The 
American Joint Committee on Cancer TNM system categorises bladder cancer based on growth into 
the bladder wall (T), spread to neighbouring lymph nodes (N) and metastases (M). Information from 
these categories is then used to evaluate the overall stage of the disease from stage 0 to IV (Table 1). 
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Table 1: Bladder cancer stages. Information from taken from (Team, 2016) 
Category Stage Description, including tumor coverage 
Ta, N0, M0 Stage 0a Non-invasive papillary carcinoma – hollow centre of the bladder 
Tis, N0, M0 Stage 0is Flat, non-invasive carcinoma (carcinoma in situ) – inner bladder 
lining 
T1,N0, M0 Stage I Invasive – connective tissues beyond the urothelial lining 
T2a or T2b, 
N0, M0 
Stage II Invasive – inner half (T2a); outer half (T2b) of the muscular region 
T3a, T3b, T4a, 
N0, M0 
Stage III Invasive – fatty tissue region visible with microscope (T3a); readily 
visible (T3b); spread to prostate, uterus and/or vagina (T4a) 
T4b, N0, M0, 
N1-N3, M1 
Stage IV Invasive / metastatic – Pelvic or abdominal wall (T4b); single pelvic 
lymph node (N1); ≥ 2 lymph nodes (N2); iliac arterial lymph nodes 
(N3); beyond the bladder to distant sites like bones, liver or lungs 
Note: N0 and M0 denotes that lymph nodes and distant sites (metastatic tumors) were not affected, 
respectively 
Eble et al graded BCs based on cell morphology into G1, G2 and G3, with G1 being the most well 
differentiated, while G3 is the least differentiated BC having the greatest risk of progression (Eble et 
al., 2004). Recently, WHO proposed a new grading classification for  BC based on improved 
knowledge of its pathology and genetics (Figure 3), where “urothelial dysplasia” and “urothelial 
proliferation of uncertain malignant potential” were included as well defined forms of non-invasive 
urothelial lesions (Moch et al., 2016).  
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Figure 3: The 2016 WHO Classification of Bladder Cancer (details extracted and presented in a 
different format) (Moch et al., 2016) 
4 Management of bladder cancer 
BC treatment is dependent on the stage and severity of disease (Sharma, 2014). The UK National 
Institute for Health and Care Excellence (NICE) has produced guidelines regarding the diagnosis and 
treatment of BC. It recommends that both cystoscopy and urine cytology is needed in order to 
diagnose BC as cystoscopy alone may miss some tumours such as CIS (NICE, 2015). The extent of BC 
progression is identified using computer tomography (CT) or magnetic resonance imaging (MRI) 
techniques. NMIBC is initially treated by TURBT (Lerner and Au, 2008; NICE, 2015). Patients with a 
low risk of disease recurrence post-surgery may be followed up with cystoscopic surveillance alone, 
whilst those in the intermediate and high risk categories are treated with intravesical chemotherapy 
(mitomycin C) or immunotherapy (BCG) (Lerner and Au, 2008). The latter triggers an immune 
response that ensures future recognition of BC cells, and this treatment has been proven to prevent 
progression in about 85% of BC cases. 
 
5 Intravesical Formulations 
 The effectiveness of bladder cancer therapeutic dosage forms depends on their ability to overcome 
the urothelium as well as the drug having suitable physicochemical properties such as molecular 
weight (≤ 200 Da), water or lipid solubility, aqueous / organic phase partition coefficient (-0.4 to -0.2 
or -7.5 to -8.0) and pH 6 to 7 (GuhaSarkar and Banerjee, 2010). Also, the surface charge of drug 
carriers influences their cellular uptake, for example, positively charged nanoparticles (NPs) are 
taken up by cells and readily absorbed into tissues in preference to anionic or neutral NPs (He et al., 
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2010; B. Kim et al., 2010). The uptake of such drug cargos may be prevented by poor interaction with 
biorecognitive moieties that facilitate cellular internalisation (Khandelwal et al., 2009); in addition to 
lack of electrostatic interaction between oppositely charged carrier and bladder mucosa. 
5.1 Conventional formulations 
The surgical implantation of drug loaded gels into BC patients was expensive and unacceptable 
(Singh and Lee, 2014). So, local drug delivery using drug instillation via a catheter was adopted which 
permits easy bladder accessibility and avoids surgery (Shen et al., 2008). The usual volume of drug 
formulation instilled intravesically is approximately 50 mL (Senyigiti et al., 2015) and micturition is 
prevented for at least 1-2 h for effective drug transport into the underlying cancerous tissues (Tyagi 
et al., 2006). Nevertheless, the instilled drug becomes diluted due to residual urine which is often 
present in the human urinary bladder and/or is washed out prematurely (Grabnar et al., 2006). 
These limitations mean that frequent catheter insertion, decreased dosing interval and eventual 
irritation of the urethral lining and possible urinary tract infection are possible complications of 
intravesical drug delivery (Martin et al., 2014). Also, conventional drug carriers such as microspheres 
(Bogataj et al., 1999; Le Visage et al., 2004) and gelatin nanoparticles (Lu et al., 2004b) display poor 
drug loading and uncontrolled drug release profiles.  
5.2 Advanced formulations  
Hydrophilic drugs are readily soluble in the aqueous urine medium of the bladder but their 
permeability and cellular uptake is limited due to the lipophilic nature of the urothelial tissues. Thus, 
chemical enhancers such as dimethyl sulfoxide (DMSO) have been used to improve the cellular 
uptake of BC chemotherapeutics such as doxorubicin and cisplatin into malignant bladder tissues 
(Giannantoni et al., 2006). However, their use is now less favourable because of unwanted side-
effects such as frequent and painful urination (GuhaSarkar and Banerjee, 2010). Also, hydrophobic 
drugs such as paclitaxel formulated with DMSO for improved solubility and urothelial permeability 
are associated with painful sensation post intravesical instillation (Parkin et al., 1997).  
Therefore, smart drug carriers were developed to improve the solubility of lipophilic drugs; 
urothelial permeability of hydrophilic drugs; urothelial adhesion of drug carriers as well as drug 
uptake / permeation into malignant tissues for prolonged periods of time. They include amphiphilic 
copolymer based solubilised systems (Tamura et al., 2015), surface modified particulate systems 
(Cook et al., 2015; Lu et al., 2015; Martin et al., 2014, 2013; Neutsch et al., 2013; Zhang et al., 2014), 
and composite particulate and hydrogel systems (Lin et al., 2014; Men et al., 2012; Senyigiti et al., 
2015; Zhang et al., 2013)(Table 2).  
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Table 2: Overview of intravesical formulations explored for bladder cancer therapy 
Class Agent Material Dosage form References 
Amphiphilic 
copolymer 
based 
solubilised 
systems 
Paclitaxel Poly (2-methacryloyloxyethyl 
phosphorylcholine-co-n-
butylmethacrylate) diblock 
copolymer (30mol% MPC 
unit: 70 mol% hydrophobic 
BMA unit) 
Ionotropic 
solution 
(Tamura et 
al., 2015) 
Surface 
modified  
particulate 
systems 
 
 
 
 
 
Belinostat PGON, PLGA Nanoparticles (Martin et 
al., 2013) 
Doxorubicin ß-cyclodextrin, mesoporous 
silica 
Nanoparticles (Zhang et 
al., 2014) 
Survivin 
SiRNA 
Chitosan, PLGA Nanoparticles (Martin et 
al., 2014) 
Stearoyl 
Gemcitabine 
Wheat Germ Agglutinin, 
PLGA 
Microparticles (Neutsch et 
al., 2013) 
Doxorubicin 
 
Copolymer of 2-
(acetylthio)ethylacrylate and 
2-hydroxyethylmethacrylate 
Thiolated 
Microgels 
(Cook et al., 
2015) 
Docetaxel Amine functionalized 
polyacrylamide 
Nanogels (Lu et al., 
2015) 
 10-
hydroxycam
ptothecin 
Poly (L-lysine)-poly (L-
phenylalanine-co-L-cysteine) 
Nanogels (Guo et al., 
2016) 
Composite 
particulate 
and hydrogel 
systems 
Adriamycin Poloxamer 407 (triblock 
copolymer), sodium 
hydrogen carbonate, HPMC, 
Human Serum Albumin 
Floating 
hydrogel-
nanoparticle 
system 
(Lin et al., 
2014) 
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Bacillus 
Calmette-
Guérin 
CS, β-glycerophosphate, 
magnetite 
Mucoadhesive 
nanoparticle - in 
situ gelling 
system 
(Zhang et 
al., 2013) 
Deguelin DOTAP, monomethoxy poly 
(ethylene glycol)-poly (Ɛ-
caprolactone) NP + Pluronic 
F127 hydrogel 
Mucoadhesive 
nanoparticle - in 
situ gelling  
system 
(Men et al., 
2012) 
Gemcitabine 
HCl 
Chitosan-thioglycolic acid 
conjugate based NPs + 
chitosan gel / Poloxamer gel 
Thiolated 
nanoparticle- gel 
/ in situ gelling  
system 
(Senyigiti et 
al, 2015) 
Liposomal 
systems 
Paclitaxel Soya phosphatidylcholine, 
gellan gum 
Liposomes / ion-
triggered gelling 
system 
(GuhaSarkar 
et al., 2017) 
 
5.2.1 Amphiphilic copolymer based solubilised systems 
Solubilised systems are isotropic solutions of a substance in a state of thermodynamic stability 
generated by dispersing the sparingly soluble substance in an amphiphilic material (Tadros, 2013). 
Cremophor is conventionally used to improve the solubility of paclitaxel (PTX-CrEL) in the 
physiological fluid but its use is limited by adverse effects as well as by reduced drug permeation 
across the mucosal lining due to drug entrapment in polymeric micelles (Knemeyer et al., 1999). 
However, the amphiphilic copolymeric delivery system, poly(2-methacryloyloxyethyl 
phosphorylcholine-co-n-butyl methacrylate (PMB30W) has been proven to be non-toxic with 
improved paclitaxel uptake into mammalian cell lines during in vitro studies (Goda et al., 2010; Wada 
et al., 2007). PTX-30W was formulated by solubilising paclitaxel (PTX) in PMB30W in order to 
improve its aqueous solubility, safety and antitumor activity (Tamura et al., 2015).  In vitro studies 
using MBT-2 BC cells to compare cytotoxicity of PMB30W and Cremophor (CrEL) to BC cells showed 
that PMB30W (1%) displayed no toxic effect to the cells while dose associated toxicity was reported 
with CrEL after 72 h of instillation. This was confirmed by the lactate dehydrogenase (LDH) activity 
assay, detecting 0% and 65% LDH release for PMB30W and CrEL, respectively, in the same study 
(Tamura et al., 2015).  
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The ability of an orthotopic bladder cancer mouse model (implanted with MBT-2 BC cells) to mimic 
the human BC environment has been confirmed in several studies (Kikuchi et al., 2007; Matsushima 
et al., 2011). This orthotopic model of BC was established through transurethral implantation of 
MBT-2 BC cells into mice. During ex vivo studies, mice were treated with various formulations (50 µL 
of 2mg/mL PBS, PTX-30W and PTX-CrEL) at predetermined time intervals and killed after 22 days to 
determine the degree of tumor growth or regression (Tamura et al., 2015). It was shown that PTX-
MBA improved tumor regression (more than 2 folds) in comparison with PTX-CrEL (Tamura et al., 
2015). Also, some of the mice were sacrificed 30 min post intravesical drug instillation and the 
degree of drug uptake into tumour tissues quantified using liquid chromatography using a tandem 
mass spectrometer, was shown to be remarkably lower in PTX-CrEL than in the PTX-30W group of 
mice (4.905 ± 2.412 µg/g vs 7.719 ± 3.274 µg/g).This revealed improved selectivity of the novel 
paclitaxel carriers for malignant tissues (Tamura et al., 2015). However, studies related to the 
resistance of the delivery system to urine dilution or wash-out were not evaluated and periodic urine 
voiding and residual urine in the bladder may have affected product performance. Also, drug release 
studies were not carried out, thus the pattern of drug release is unknown. This makes it difficult to 
ascertain that the drug would be released in a controlled manner, which is a critical parameter for 
improved formulations that would reduce dosing frequency. 
5.2.2 Surface modified particulate systems 
5.2.2.1 Lectin modified particulate systems 
Glycans and lectins are biological entities that are sensitive and responsive to bacterial and 
malignant invasion by destroying them through endocytosis, where they interact and adhere onto 
mannose receptors (Bies et al., 2004; Haltner et al., 1997; Yi et al., 2001). It is anticipated that lectins 
will be useful for malignant conditions associated with the bladder because they attach to the distal 
portion of Escherichia coli pili and destroy the E. coli in bacterial urinary infections (Dhakal et al., 
2008). Also, urothelial cellular uptake of plant lectin, like wheat germ agglutinin (WGA, 36 kDa), in 
pigs and humans, suggested that biologics may be delivered intravesically, as lectins are readily 
recognised  by the glycol-proteins and lipids of the urothelium and facilitate cellular uptake of a 
bioconjugate (Neutsch et al., 2011). Neutsch and co-workers surface-functionalised fluorescently 
labelled bovine serum albumin (fBSA) with WGA units and this modification influenced the urothelial 
cell (SV-HUC-1) adhesive and invasive potential of the fBSA / WGA bioconjugate (Neutsch et al., 
2012). Their cytoadhesive features were greatest when the total number of targeting ligands was 
three and such features did not increase further for bioconjugates with 4-6 WGA units (Neutsch et 
al., 2012). This glycan-modulated interaction was critical for internalization of the drug carrier (> 175 
kDa) within less than 60 minutes, with more than 40% of drug taken up via endocytosis (Neutsch et 
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al., 2012). The unchanged extent of cell adhesive properties with increased WGA units (≥ 3) may be 
due to some of their recognitive domains being sterically hindered from binding to glycosylated 
urothelial cell membranes (Neutsch et al., 2012). WGA metabolism after fBSA release might have 
taken place via lysosome degradation (Neutsch et al., 2012). 
Stearoyl gemcitabine (GEM- C18) loaded PLGA microparticles (MPs) surface modified with WGA or 
human serum albumin (HSA), WGA-GEM-C18-PLGA MPs or HSA-GEM-C18-PLGA MPs were explored 
for IDD (Neutsch et al., 2013). In vitro studies using cancerous and non-malignant cell monolayers 
showed that the WGA-GEM-C18-PLGA MPs had better cellular uptake, internalization and cytostatic 
action than HSA-GEM-C18-PLGA MPs and unmodified MPs within 3 mins of instillation. WGA-GEM-
C18-PLGA MPs also had a two-fold greater affinity towards malignant cell lines than healthy cells. The 
fluorescently labelled drug loaded WGA modified MPs and HSA based MPs required a contact time 
of 30 mins and 120 mins, respectively, to impart cytotoxic activity on low grade cancerous cell lines 
using fluorescence microscopy (Neutsch et al., 2013). WGA-GEM-C18-PLGA MPs were more resistant 
to wash-off by artificial urine, which allowed for superior retention of cytostatic effect (78 ± 12%) 
compared to free prodrug but the degree of cell inhibitory potential of the latter in the presence of 
urine was not defined (Neutsch et al., 2013). There was no significant difference in the sustained 
release effect (after 120 mins) for the three formulations (WGA- , HSA-modified and unmodified 
PLGA MPs), which could be attributed to the inability of the study design to simulate washout 
features of the urinary bladder. The WGA-modified MPs also had low drug release of 13.2 ± 1.8% 
after 5 days with most of the drug retained within the particle matrix. However, studies of 
bromodeoxyuridine antimetabolic activity (that connotes duration of drug action) suggested that 
WGA based particles require lower dose than free drug for achieving a particular degree of 
prolonged action (Neutsch et al., 2013). Also, a cell proliferation assay suggested better 
antiproliferative properties for drug loaded surface modified particles than free drug (Neutsch et al., 
2013).  
Overall, the optimisation and translation of this strategy to the clinic may be limited by the relatively 
high cost of manufacturing associated with the processing in terms of time and materials required 
for isolation and purification of the bioconjugate of interest. The bioconjugate size may be 
heterogenous resulting in immunogenic and adverse reactions. However, the authors did not 
envisage such formulation constraint. 
Recently, Apfelthaler et al evaluated a bioconjugate, WGA conjugated to fluorescein cadaverine (FC) 
labelled poly(L)glutamic acid (PGA) (WGA/FC-PGA), for bladder cancer theranostic application 
(Apfelthaler et al., 2017). PGA  may improve the solubility of the hydrophobic agents while WGA 
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favours the selective uptake of bioconjugate into malignant bladder tissues by interacting selectively 
with the glycocalyx components (N-acetyl-D-glucosamine and sialic acid) of BC cells (Wright and 
Kellogg, 1996). FC helps to track transport of the drug carrier into the cancerous cell endosome 
and/or lysosome. They confirmed earlier findings by Neutsch’s group (Neutsch et al., 2013, 2012) 
that the presence of biorecognitive moieties like WGA was critical for improved cellular uptake and 
internalization of bioconjugates into BC cells. Flow cytometry was used to evaluate the cell-binding 
ability of WGA/FC-PGA. Size exclusion chromatography was used to purify the synthesized 
bioconjugate and isolate biorecognitive fractions. Conjugate A (160 kDa) fraction, obtained with 60 
to 80 mL eluent, displayed superior cell binding efficiency relative to conjugates B – D due to the 
presence of WGA conjugated FC-PGA system. Five FC molecules per PGA were critical for adequate 
trackability of the bioconjugate as it exhibited greater cell-induced relative fluorescence intensity 
than bioconjugate with 30 FC per PGA. Conjugate A was found to be cytoadhesive at 4oC but become 
cytoinvasive at 37oC via active transport. On the other hand, conjugates C and D eluted around 90 
mL and lacked both cell adhesive and uptake properties (Apfelthaler et al., 2017). There was no 
hydrophobic agents delivered within the scope of this study, though the authors acknowledged that 
their future studies will explore optimal drug loading that will not compromise the cell binding and 
uptake features of the bioconjugate. However, they noted that there is a need for conjugate A (the 
most promising bioconjugate) to replicate a similar cytoinvasive and cytoadhesive profile when 
hydrophobic theradiagnostic agents are loaded. 
5.2.2.2 Mucoadhesive delivery systems 
Over the last decade, researchers have intensified efforts towards investigating materials with ability 
to adhere readily to mucosal surfaces because they can prolong contact time between dosage form 
and diseased site, which is desirable for intravesical formulations (Cook et al., 2015; Khutoryanskiy, 
2011; Lu et al., 2004a; Senyigiti et al., 2015). Due to their successful applications for other 
transmucosal routes of administration such as buccal, ocular and vaginal (Bonengel and Bernkop-
Schnürch, 2014), mucoadhesive systems have also been explored for intravesical delivery to enhance 
drug bioavailability and duration of action (Barthelmes et al., 2012; Cook et al., 2015; Men et al., 
2012; Zhang et al., 2013, 2014). 
5.2.2.2.1 Cationic particulate systems 
Poly[D, L-lactide-co-glycolide] (PLGA) nanoparticles have been widely used for biomedical 
applications because of their biocompatibility, biodegradability, ease of modification with polymers 
and peptides (Cheng and Saltzman, 2011; Fahmy et al., 2005), ability to protect encapsulated 
biologics or therapeutics from degradation during transit, as well as the possibility for controlled 
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release of loaded drugs (Anthony et al., 2005; Cu et al., 2011; Khan et al., 2004). Poly(guanidinium 
oxanorbornene) (PGON) is a non-toxic synthetic polymer which is comprised of cationic guanidinium 
groups and acts similarly like a peptide based cell penetration enhancer (Hennig et al., 2008). Martin 
et al explored surface functionalization of PLGA nanoparticles modified with a urothelial cell 
penetrating polymer such as PGON to improve aqueous solubility, urothelial cellular uptake, 
internalization, cytotoxic effect, and duration of action of lipophilic drugs such as belinostat, an 
histone deacetylase inhibitor (Martin et al., 2013). Belinostat promotes hyperacetylation (Martin et 
al., 2013) with intrinsic IC50 in bladder and prostate cancer cells within the range of 1 to 10 µM 
(Buckley et al., 2007; Qian et al., 2008); and inhibits BC progression to its metastatic and aggressive 
forms. All PLGA nanoparticles were 140-160 nm but PGON-modified PLGA nanoparticles (NP-
Belinostat-PGON) had superior drug loading relative to the unmodified (NP-Belinostat) and 
biotinylated chitosan conjugated nanoparticles (NP-Belinostat-Chit) by 3.3- and 6.8-folds, 
respectively (Martin et al., 2013). Ex vivo studies of fluorescently labelled NP-Belinostat-PGON using 
human ureter as well as in vivo studies with mouse bladder suggested that the uptake of NP-
Belinostat-PGON was ten times greater than that of unmodified nanoparticles (Martin et al., 2013). 
PGON improved urothelial uptake of nanoparticles by interaction with a negatively charged 
urothelial surface coated with glycosaminoglycan, or opening tight junctions of the urothelium. This 
facilitated drug transport across the urothelial membrane into underlying tissues (Martin et al., 
2013). The in vivo cytotoxic effect of PGON-PLGA nanoparticles was tested using a xenograft murine 
model generated from the UM-UC-3R human BC cell line. Tumor growth was not significant after 11 
days of treatment for NP-Belinostat-PGON, whereas the volume of tumors treated with unmodified 
PLGA nanoparticles and drug-free PGON-PLGA nanoparticles increased by at least two fold relative 
to tumors treated with NP-Belinostat-PGON. After 21 days, the volume of tumors treated with NP-
Belinostat and NP-Blank-PGON had increased by 77% and 71%, respectively, relative to NP-
Belinostat-PGON treated tumors (Martin et al., 2013). The burst release profile of the novel drug 
carrier was evident by Histone H4 hyperacetylation occurring in RT-4 (non-invasive) and T-24 (highly 
invasive with metastatic tendency) cell lines within 30 mins following the instillation of NP-
Belinostat-PGON, and the protein expression was sustained for 3 days (Martin et al., 2013). Thus, a 
lower dose of the NP-Belinostat-PGON may be used to achieve the same therapeutic index observed 
with free belinostat (Martin et al., 2013).Though the degree of tumor regression by the PGON 
surface decorated PLGA nanoparticles may correlate with their extent of cellular uptake and drug 
release,  the authors have not quantified the amount of belinostat that was taken up for the 
modified and unmodified nanoparticles. This information would be useful for determining dosage 
regimen for BC treatment using this drug carrier. 
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In a later studies, Martin et al showed that PLGA nanoparticles functionalised with low molecular 
weight chitosan (CH) , 2.5 or 20 kDa (CH2.5-PLGA or CH20-PLGA) were able to adhere onto urothelial 
surface and enhance the uptake of larger therapeutic agents like survivin siRNA (Martin et al., 2014). 
Survivin siRNA expression within urothelial cancerous cells enhanced destruction of survivin mRNA 
responsible for preventing death of cancerous cells. In vitro release studies showed the 
encapsulation efficiency of the nanoparticles modified with chitosan was superior compared to 
unmodified nanoparticles (70 vs 60 %). CH2.5-PLGA nanoparticles demonstrated a superior burst 
release profile relative to CH20-PLGA. Also, the CH20 decorated carrier displayed 10-fold lower 
siRNA release than CH2.5-PLGA nanoparticles over 13 days. During ex vivo studies, CH20-PLGA and 
CH2.5-PLGA nanoparticles displayed improved cellular uptake into UM-UC-3 BC cells in comparison 
with control PLGA nanoparticles, in the magnitude of 5-10 fold and 4-9 fold, respectively, within 120 
mins of incubation (Martin et al., 2014). During in vivo mice studies, bladder uptake was up to 14-
fold and 9-fold greater for CH20-PLGA and CH2.5-PLGA nanoparticles, respectively, compared to the 
control formulations (Martin et al., 2014). However, CH20-PLGA nanoparticles  entrapped greater 
amounts of siRNA, in addition to forming bulkier surface groups, which prevented their release and 
bioactivity (Martin et al., 2014). 
Thus CH2.5-PLGA NPs may be desirable for therapy where fast onset of action is needed followed by 
a sustained release profile over a period of time. Moreover, the amount of drug taken up into 
bladder tissues was sufficient to reduce mRNA expression and promote tumor regression. The varied 
physicochemical interaction between the surface of carriers and the urothelial membrane is 
responsible for the different degree of tumor regression, sustained release, and duration of action 
observed. Their findings indicated that chitosan chain length used for surface modification 
influenced the carrier’s drug loading, release, and cellular uptake behaviour. 
 
5.2.2.2.2 Thiolated particulate systems 
Some hydrophilic polymers such as chitosan are intrinsically mucoadhesive due to its cationic amino-
groups which promote interaction with mucin (Barthelmes et al., 2011a; Sogias et al., 2008; Van der 
Lubben et al., 2001). Nevertheless, functional groups such as thiols (Barthelmes et al., 2011b; 
Bernkop-Schnürch and Greimel, 2005), acrylates (Brannigan and Khutoryanskiy, 2017; Davidovich-
Pinhas and Bianco-Peled, 2011), maleimide (Tonglairoum et al., 2016) and catechols (Xu et al., 2012) 
have been explored to chemically modify polymers in order to improve their mucoadhesion. 
Irmukhametova et al reported the synthesis of thiolated nanoparticles using self-condensation of 3-
mercaptopropyltrimethoxysilane (Irmukhametova et al., 2011), which were subsequently used by 
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Mun et al (Mun et al., 2016) to study retention on porcine bladder surface. Thiol-ene click chemistry 
involving interactions between pentaerythritol tetraacrylate and tetrakis (3-mercapto-propionate) 
were employed by Štorha and co-workers to produce thiolated nanoparticles (Štorha et al., 2013) 
that were shown to be adhesive to porcine bladder mucosa.  However, these nanoparticles 
(Irmukhametova et al., 2011; Štorha et al., 2013) have not been explored for formulation of 
anticancer agents for intravesical BC therapy. 
Zhang and co-workers generated thiol-functionalised cyclodextrin based mesoporous silica 
nanoparticles (MSNPs-CD-(NH2)-SH) for potential BC treatment and reported that they possess 
superior mucoadhesion compared to hydroxyl and amino-functionalised NPs [MSNPs-CD-(OH) and 
MSNPs-CD-(NH2)] during mucin-nanoparticles interaction studies (Zhang et al., 2014). In vitro MTT 
cytotoxic testing on UMUC3 BC cells showed that the IC50 for doxorubicin loaded thiolated NPs (Dox- 
MSNPs-CD-(NH2)-SH ) and free doxorubicin were 3.92 ± 1.06 µg mL-1 and 0.45 ± 0.05 µg mL-1, 
respectively (Zhang et al., 2014). The gradual release of doxorubicin from the nanoparticulate 
formulation into the endosomes /lysosomes of the BC cells may be responsible for the IC50 of about 
3.92 µg mL-1 reported for Dox- MSNPs-CD-(NH2)-SH. However, IC50 values for MSNPs-CD-(OH) and 
MSNPs-CD-(NH2) also evaluated in the study, were not provided. Thus there were no means of 
establishing the cytotoxic superiority of doxorubicin loaded thiolated drug carriers over amino- and 
hydroxylated nanoparticles. Also, in vitro drug release studies revealed that doxorubicin was 
released faster (63%) from thiolated nanoparticles deposited onto porcine bladder tissues incubated 
in simulated urine conditions (pH 6.1) relative to PBS (pH 7.4), with drug release of 13% after 48h 
(Zhang et al., 2014). However, studies that use artificial urine may be more reliable as it is closest to 
the physiological environment of the bladder.  
Cook et al, co-polymerised a thiol-bearing monomer, 2-(acetylthio)ethylacrylate (ATEA) with 2-
hydroxyethylmethacrylate (HEMA) using ethylene glycol dimethacrylate as a cross-linker (Figure 4) 
to generate  635-977 nm thiolated microgels (Cook et al., 2015). These microgels were found to 
exhibit high doxorubicin encapsulation efficiency (75-86%), good colloidal  stability, excellent bladder 
mucoadhesion as well as sustained drug release over 300 min. Doxorubicin was released from the 
insoluble matrix through Fickian diffusion established from the Higuchi drug release model. 
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Figure 4: Synthesis of thiolated microgels: (a) Synthetic route to ATEA, a protected thiomonomer. 
(b) Polymerisation to form ATEA: HEMA copolymer microgels, displaying the pendant 
functionalities present. (c) Deprotection of ATEA using sodium thiomethoxide to yield thiol-
bearing microgels. (i) Potassium thioacetate, acetone, 24 h. (ii) Acryloyl chloride, trimethylamine, 
DCM, reflux, 24 h. (iii) Ammonium persulfate, ethylene glycol dimethacrylate, water, 70oC, 6 h. (iv) 
Sodium thiomethoxide, methanol, 30 min. This figure is reproduced from Cook et al., (2015). 
Reproduced with permission from the Royal Society of Chemistry. 
Also, the retention of doxorubicin loaded microgels on the bladder tissues was modulated by 
variation of the molar proportions of both monomers (ATEA & HEMA) to generate microgels with 
desirable thiol content. For example, microgels with the greatest and least degree of thiolation were 
achieved with 80 mol% and 30 mol% ATEA, respectively (Cook et al., 2015). The former resisted 
wash off by artificial urine during ex vivo porcine bladder mucoadhesion studies compared with the 
latter. This may be associated with a greater amount of thiol groups forming covalent disulphide 
bridges with the cysteine-rich regions of urothelial mucins as mucosal adherence was independent 
of surface charge or polarity of carrier. The 30 mol% and 80 mol% ATEA / HEMA based microgels had 
capacity for loading up to 2.5 mg mL-1 and 2.7 mg mL-1 doxorubicin, respectively (Cook et al., 2015), 
which was greater than the therapeutic doses of doxorubicin (1- 2 mg mL-1; 25-100 mL solution) 
(Amling, 2001; Lamm et al., 2005). However, future in vivo studies are desirable to facilitate further 
development of these drug carriers. 
Cationic amine-functionalised polyacrylamide (PAm-NH2) based nanogels were investigated for 
intravesical delivery of docetaxel (Lu et al., 2015) due to their safety, mucoadhesive properties and 
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sustained release potential. They were prepared as a lyophilized solid readily dispersible in water or 
phosphate buffer saline (PBS). These materials had high drug loading (> 90%) with an initial burst 
release within 9 h and a sustained release over 9 days when formulations were put in a dialysis 
membrane and drug release evaluated in artificial urine over predetermined time intervals (Lu et al., 
2015). Docetaxel loaded functionalised carrier (DTX-Pam-NH2) displayed superior inhibition towards 
UMUC3 cells relative to T24 cells, with a minimum inhibitory concentration (IC50) of 5.6 ng/mL vs 
535.6 ng/mL) over 4h and the difference became more pronounced with an exposure time of 72 h, 
with a calculated IC50 of 1.6 ng/mL and 11.6 ng/mL, respectively. Also, the cellular uptake of 
fluorescently labelled DTX-Pam-NH2 nanogels into UMUC3 cells at 37oC was more pronounced than 
into the T24 cells in a concentration dependent manner. This finding was also confirmed in ex vivo 
studies using porcine bladder tissues, where persistent green fluorescence on bladder tissues 
suggested the adhesion of the fluorescent carrier onto bladder urothelium. The treatment of intact 
bladder urothelium with the novel formulation also confirmed its safety when analysed using 
scanning electron microscopy as it induced only mild disruption of the urothelial tissues (Lu et al., 
2015). However, the preparation of nanogels was time-consuming as the preparation took about a 
week. Also, the amine functionalised surface may not have superior mucoadhesive features because 
its mode of interaction with the bladder mucosa would be via electrostatic attraction rather than 
covalent bonding which is stronger (Bernkop-Schnürch and Greimel, 2005).  
Recently, Mun et al developed a new method for evaluating the retention of thiolated and 
PEGylated silica nanoparticles on porcine bladder epithelium during ex vivo studies as drug 
containing or blank formulations are being washed off using artificial urine (Mun et al., 2016). The 
parameter “Wash Out50” (WO50) represented the volume of biological fluid (such as artificial urine) 
required to detach 50% of the adhered particulate carrier from a mucosal tissue. The in vitro studies 
also identified chitosan with superior WO50 value and mucoadhesive property relative to thiolated 
nanoparticles and dextran (89 mL vs 36 mL vs 7 mL). The mucoadhesiveness of thiolated silica NPs 
was decreased with surface decoration with PEG and porcine bladder mucoadhesion reduced with 
increase in PEG molecular weight (5000 vs 750 Da) resulting in WO50 of 8 mL and 29 mL, respectively 
(Mun et al., 2016). 
Guo et al studied 10-hydroxycamptothecin (HCPT) loaded cationic cross-linked polypeptide (poly(L-
lysine)-poly (L-phenylalanine-co-L-cysteine) [PLL-P (LP-co-LC)] nanogels (HCPT/NG) for intravesical 
delivery. The poly(L-lysine) segment of the peptide is positively charged and interacts favourably 
with negatively-charged bladder mucosa while PLL-P (LP-co-LC) mimics cell penetrating peptides by 
promoting drug uptake into BC cells (Shin et al., 2014). The drug carrier had a particle size in a nano-
range (≈ 65 nm); was positively charged (+16.3 ± 1.4 mV) as well as displayed good drug loading 
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capacity and efficiency of 30.6 and 88.2 % (w/w), respectively. Based on Confocal Laser Scanning 
Microscopic (CLSM) and microplate reading method of analysis, HCPT/NG was taken up into BC cells 
via endocytosis and drug was efficiently delivered into T24 cell nuclei within 6 h, while the free drug 
formulation remained into the cytoplasmic region (Guo et al., 2016). During in vitro studies, T24 BC 
cells were treated with HCPT and HCPT/NG for 24 h and the cytotoxic effect of the formulations was 
investigated using MTT assay. The drug loaded nanogel showed greater cytotoxic effect than the 
free drug (IC50 values of 2.7 mg / L vs. 7.9 mg/L). With the in vivo studies using orthotopic BC model, 
HCPT/NG demonstrated remarkably improved antitumor activity using flow cytometric cell analysis, 
with cell death occurring predominantly in the nanogel treated regions relative to that treated with 
free drug. In addition, the drug loaded nanogel exhibited superior tumor necrotic region (46.3 ± 
2.2%) relative to the cells exposed to free drug, up to 3.8-fold increase. The in vivo biodistribution of 
the drug carriers was studied: six hours post treatment with nanogel and / or drug, the mice were 
sacrificed and their bladder and other major organs were excised, homogenised and evaluated by 
HPLC. The HCPT/NG were preferentially retained in the bladder and rarely in other organs, displaying 
3.2-fold greater drug concentration in the bladder than that of the free drug-treated mice. This 
finding also correlates with the improved safety of the drug carrier due to targeted drug delivery, 
further confirmed by the insignificant changes in body weight throughout the studies (Guo et al., 
2016). This drug carrier appears promising for the treatment of superficial BC. However, in vitro drug 
release and in vivo mucoadhesive profile of HCPT or HCPT/NG were evaluated using PBS. It will be 
more physiologically relevant if artificial urine was used instead of PBS.  
 
5.2.3 Composite system of nanoparticles and hydrogel 
Composite systems of nanoparticles and hydrogels  were explored to combine the benefits of both 
formulations including improved drug loading, release, mucoadhesion and urothelial uptake. 
Hydrogels are three-dimensional hydrophilic or amphiphilic polymer networks, prepared by physical 
or chemical crosslinking of polymers. These materials exhibit excellent ability to retain water or 
biological fluids (Kopeček, 2007; Yu and Ding, 2008). They are soft, flexible and biocompatible; this 
makes them readily fabricated as building blocks for soft tissues (Khetan et al., 2013; Oommen et al., 
2013; Rice et al., 2013). The physically cross-linked hydrogels are more readily eliminated after drug 
release and uptake into the urothelial tissues, than hydrogels prepared using covalently bonded 
polymers. However, a balance is required between prolonged duration of action and 
biodegradability so that covalently linked hydrogels do not cause any harm to the body. 
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In situ gelling systems are liquid formulations with flowing tendency at room temperature and form 
gels at physiological environment in response to various stimuli such as pH, enzymes or 
temperature. In recent years, temperature has become the commonly explored stimuli for such 
formulations (He et al., 2008; Kim and Park, 2002; Narendra and Lee, 20014), where sol-gel 
transition takes place at 37oC (within the body). It is desirable that dosage forms for mucosal delivery  
(including the intravesical route) have gelation temperature within the range of 30oC to 36oC (Choi et 
al., 1998). Over the last decade, biomedical researchers have explored these systems for drug / 
biomolecule delivery (Gong et al., 2012; Taylor et al., 2010; Wang et al., 2013) and tissue engineering 
(Niranjan et al., 2013) because they are readily manufactured, exclude use of organic solvents, 
administered in a minimally invasive mode, and provide sustained release (Supper et al., 2013).Their 
liquid consistency also allows their easy mixing with therapeutic agents before administration to a 
patient (Nguyen and Lee, 2010). Thus they have been employed for IDD, serving as drug reservoir, 
from where drug is released steadily over extended period of time. 
5.2.3.1 Floating Composite systems of NPs and hydrogels 
Adriamycin, an anthracycline antibiotic, is useful for reducing BC recurrence (Dalbagni, 2007) when 
administered intravesically after transurethral resection but its application was limited because it 
causes irritation and scarring of the bladder; additional problem with this drug is its rapid release  
(Eto et al., 1994). Floating strategies were used for oral formulations to improve residence time of 
drugs in the gastrointestinal tract (Pawar et al., 2011; Prajapati et al., 2013; Singh and Kim, 2000). 
Thus composite nanoparticle-hydrogel delivery system, with in situ gelling and floating potential 
within the bladder , was designed to serve as a drug depot to release adriamycin gradually and 
prevent urinary obstruction associated with the high viscosity of conventional non-mucoadhesive 
hydrogels (Lin et al., 2014). The safety of adriamycin has also been improved by formulating it as 
human serum albumin based nanoparticles (103 nm) that are loaded into Poloxamer 407 (P407) and 
hydroxypropyl methyl cellulose (HPMC) based thermosensitive gel (Lin et al., 2014). The P407 
facilitated gelation through micellar packing and entanglements (Alexandridis and Hatton, 1995; 
Mortensen, 1993), while HPMC enabled attachment of the nanoparticles to the bladder wall and 
prolonged erosion of the gel which ensured sustained drug release. One of the components of this 
formulation (sodium hydrogen carbonate) enables the drug carrier to float in urine environment. It 
produces CO2 microbubbles in acidic medium which enables the hydrogel system to float, thereby 
preventing urinary obstruction (Lin et al., 2014). Nanoparticles with adriamycin formulated using  
P407 and HPMC were reported to undergo sol-gel transition within the shortest time possible, 
achieving gelation temperature (GT) of 10oC and gelation time (Gt) of 2 mins when evaluated at 
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37oC, in comparison with other evaluated carriers (nanoparticles-adriamycin or non-floating 
hydrogel), with  GT of 12 to 18oC  and Gt of 2-5 mins at 37oC. 
 
The amount of drug released into the urine of rats as well as the amount retained in their bladder 
following intravesical administration of a suspension of adriamycin nanoparticles and adriamycin 
loaded nanoparticles dispersed into in situ gelling liquid showed that the composite nanoparticles-
hydrogel system facilitated a controlled drug release with 81.87% drug released over 10h compared 
to the nanoparticles (with loaded drug released instantly) (Lin et al., 2014). The in vitro and in vivo 
drug release studies did not correlate well due to the disparity in the volume of evaluation medium 
as well as hydrogel volume used. This is because the in vivo studies had to use hydrogel volume of 
0.1 mL that can be accommodated in rat’s bladder (volume of ≤ 1 mL), while the in vitro studies used 
400 mL release medium and hydrogel volume of 12 mL applicable to humans. However, to achieve 
this excellent retention effect urine needed to be acidified for the formulation to float. This may be 
less acceptable due to potential irritation of the bladder caused by low pHs (Lin et al., 2014). Thus 
floating in situ gelling drug carrier with sustained release profile at pH 6-7 (intrinsic pH of the bladder 
environment) would be worth investigating in the future.  
5.2.3.2 Non-floating, mucoadhesive composite systems of polymeric nanoparticles and 
hydrogels 
Some authors investigated delivery systems that form non-floatable gels in situ but made of 
materials that do not potentially obstruct urine elimination as they are flexible and steadily dissolved 
in urine over time, though mucoadhesive for sufficient length of time to allow for drug uptake into 
urothelial membranes. 
Chitosan (CH) formulated with β-glycerophosphate disodium salt (β-GP) is an example of physically 
cross-linked temperature-responsive gelling system (Figure 5) that has been evaluated by some 
researchers (Abdel-Bar et al., 2014; Khodaverdi et al., 2012; S. Kim et al., 2010). They suggested 
molecular mechanism for the gelation process in terms of increased  electrostatic repulsion between 
chitosan macromolecules in the presence of negatively charged ß-GP which also stabilise the 
resultant hydrogel system as well as chitosan intermolecular hydrophobic and hydrogen bonds 
(Lavertu et al., 2008; Qiu et al., 2011). It was suggested by Supper and co-workers (Supper et al., 
2013) that these molecular interactions have not explained the influence of temperature on the 
gelation process, despite the fact that some authors (Patois et al., 2009; Schuetz et al., 2008) have 
established the role of polyol moiety of gelling material in their thermo-sensitivity.  
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Figure 5: Schematic diagram showing gelation process of chitosan/ß-glycerophosphate mixture at 
37oC 
Therapeutic agents have been delivered locally and systemically using thermoresponsive chitosan-β-
GP in situ gelling system (Abdel-Bar et al., 2014; Aliaghaie et al., 2012; Khodaverdi et al., 2012; S. Kim 
et al., 2010; Peng et al., 2013). However, drug delivery application of chitosan-ß-GP systems has 
been limited because of poor drug loading, cellular uptake, rapid drug release and short-lived 
activity of loaded drugs. (Park et al., 2012; Ruel-Gariépy and Leroux, 2004). Thus they have not been 
used for IDD.  
Magnetic delivery system was studied for the adjuvant treatment of superficial BC. BCG powder and 
magnetite (Fe3O4) nanoparticles were incorporated into chitosan / β-GP solution. The 
nanoparticulate component targeted the carrier to bladder tissues under the influence of magnetic 
field. The resultant Fe3O4-BCG-chitosan / β-GP system formed gel in situ and resisted urine wash-off 
(Zhang et al., 2013). BCG loaded magnetic gel dosage form stimulated greater Th1 immune reaction 
with increased expression of interleukin-2 (IL-2, 149.3 ± 8.06 pg/mL) and interferon ɣ (IFN-ɣ, 373.47 
± 40.53 pg/mL) in the urine and superior antitumor activity (tumor volume of 0.53 ± 0.27 mm3) 
compared to conventional BCG solution with “1L-2” of 98.84 ± 7.03 pg/mL; IFN-ɣ of 220.28 ± 54.19 
pg/mL and tumor volume of 1.82 ± 0.48 mm3. The duration of BCG residence within the bladder 
tissues was also extended beyond one month, evident by the CD4+ lymphocyte levels detected in 
submucosal regions:  3913 ± 467 lymphocytes were recorded for magnetic BCG nanoparticle-
hydrogel carrier compared to 2578 ± 269 lymphocytes when BCG solution was used.  
Chitosan has an intrinsic mucoadhesive property and may be responsible for improved antitumor 
immune reaction exhibited by the magnetic carrier in the bladder (Zhang et al., 2013). Also, tight 
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junctions of the urothelial membrane are loosened up due to their interaction with chitosan, 
thereby increasing and sustaining local drug concentration (Rosenthal et al., 2012). In vitro release 
studies were not carried out due to the lack of reliable techniques used for detection and 
quantification of BCG. Moreover, the BCG  radiolabelling technique explored by Shen et al was not 
helpful (Shen et al., 2007). So, initial burst release profile was suggested based on persistent 
cytokine expression in rat urine up to 48 hours during in vivo studies. The burst release profile of 
BCG may result in adverse reactions. So, further studies should be carried out to ascertain if the 
delivery system is appropriate for BCG or alternative method of BCG quantification may be helpful 
for dosage determination. 
Deguelin has been employed for chemotherapy of lung, breast and colon cancer due to its 
antiangiogenic potential (Lee et al., 2005; Oh et al., 2007; Peng et al., 2007). However,  its clinical use 
is limited because of its hydrophobicity as well as potential side effects associated with high drug 
dose (Lee et al., 2005). N-[1-(2, 3-Dioleoyloxy) propyl]-N, N, N-trimethylammonium chloride (DOTAP) 
has cationic hydrophilic head and hydrophobic chain and nanoparticles formulated using this 
amphiphilic material  are able to solubilise lipophilic drugs and enhance urothelial uptake so that the 
dose required for the therapy is reduced, minimising toxicity effects. This justifies their acceptance 
by FDA for the gene-based treatment of lung cancer (Díez et al., 2009; Gopalan et al., 2004; Simberg 
et al., 2004). 
Men et al reported the improved deguelin’s aqueous solubility and residence time in the bladder 
using the formulations composed of amphiphilic DOTAP and monomethoxyl poly(ethylene glycol)-
poly(Ɛ-caprolactone (MPEG-PCL) [DMP] based nanoparticles and thermosensitive in situ gelling 
Pluronic F127 (F127) (Men et al., 2012). F127 hydrogel improved urothelial uptake and tissue 
absorption of deguelin while cationic DOTAP/MPEG-PCL nanoparticulate component facilitated 
sustained drug release (Kabanov et al., 2002). Deguelin loaded nanoparticles had encapsulation 
efficiency of 98.2% but rate of loading drug into these nanoparticles was low (4.9%). In vitro drug 
release studies were performed using dialysis membrane maintained in a water-bath containing PBS 
(pH 7.4) and 0.5% w/w Tween 80. This formulation formed gel readily at 25oC in vitro and 
fluorescent gel was observed in mice within 10 minutes of intravesical administration which 
sustained for 2h (Men et al., 2012). In vitro cellular uptake studies using DOTAP modified in situ 
gelling formulation and unmodified nanoparticles loaded with fluorescent coumarin-6 (with similar 
hydrophobic nature to deguelin) showed that the former was readily taken up by T24 BC cells than 
the unmodified nanoparticles. In vivo studies using mice confirmed cellular uptake of fluorescent 
model drug loaded formulation based on fluorescence observed within sections of bladder tissues. 
The tolerability of deguelin was improved with the intravesical administration of the novel drug 
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loaded formulation because similar drug amount (2mg kg-1) given intravenously to mice, killed them. 
Thus, D/DMP-F may be safer, effective without causing urethral blockage due to its gradual 
elimination from the bladder (Men et al., 2012). 
Ṣenyiğit et al  have employed chitosan-thioglycolic acid conjugate (CH-TGA) to prepare nanoparticles 
(CH-TGA NPs) and incorporated them into 2% chitosan gel (CH-TGA NPs/CH) or in situ gel forming 
poloxamer (CH-TGA NPs / Plx gel) for improved intravesical delivery of gemcitabine hydrochloride 
(Gem-HCl) (Senyigiti et al., 2015). Gem-HCl nanoparticles  had greater drug loading than DMP 
nanoparticles evaluated by Men et al (Men et al., 2012) (9.4% vs 4.9%) but the latter had greater 
encapsulation efficiency than the former (98.2% vs 19.2%). This finding may be associated with the 
differences in the physicochemical properties of the formulation. CH-TGA NPs/CH gel was more 
resistant to dilution by artificial urine (Tyrode solution) than CH-TGA NPs / Plx gel at 37oC based on 
rheological frequency sweep data (Storage modulus 15Pa vs 6Pa). In vitro Gem-HCl release studies 
also suggested that the rate of drug release following dispersal of nanoparticles into CH-gel and Plx 
gel decreased by a magnitude of 1.5 and 2.6, respectively as well as release rate of 33.4 ± 5.0% vs 
19.6 ± 1.6% in 4 hours (Senyigiti et al., 2015). During bioadhesion test using bovine bladder mucosa, 
CH-TGA NPs/CH gel also had improved bioadhesive properties (in terms of its force of detachment 
from the bladder tissues) compared to Plx gel based carrier (1.003 ± 0.048 N·mm vs 0.378 ± 0.022 
N·mm). The incorporation of the drug carriers with Tyrode solution resulted in a 51% and 80% 
reduction in bioadhesive properties, respectively (Senyigiti et al., 2015). Greater percentage of the 
drug permeated the bladder mucosa for the CH-gel based carrier compared to Plx-gel (33.16 ± 5.11% 
vs 18.78 ± 1.97%) during ex vivo studies. Thus CH-TGA NPs/CH gel may be a potential intravesical 
delivery system for Gem-HCl in order to improve efficacy and drug residence time within the 
bladder. This investigation was intended to mimic the behaviour of the proposed formulation within 
the urine containing bladder environment. However, the gelation time reported for Plx gel-Tyrode 
solution and CH-TGA NPs/Plx gel –Tyrode solution (457 ± 4 seconds vs 483 ± 2 seconds) at 37oC was 
quite unexpectedly low for formulations with gelation temperature of 51.7±1.0oC and 53.7±1.9oC, 
respectively. 
5.2.4 Liposomal systems 
Liposomes were not usually explored for intravesical drug delivery because of their instability in 
human urine. Recently, Nakamura’s group modified cationic liposomal surfaces with cholesteryl-PEG 
to overcome their urine aggregation and promote uptake into urothelial tissues (Nakamura et al., 
2017). N-(carbonyl-methoxypolyethyleneglycol 200)-1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-PEG (DSPE-PEG) based formulations were the most resistant to aggregation 
in the presence of human urine relative to 1,2-distearoyl-sn-glycerol, methoxy-PEG 2000 (DSG-PEG) 
26 
 
26 
 
and cholesterol-PEG (Chol-PEG). This finding was due to the superior flexible conformation of DSPE-
PEG in comparison to DSG-PEG and Chol-PEG. Also, the rich density of negative charge on DSPE-PEG 
shields the cationic liposomes thereby enhancing stability in the urine. Additionally, fluorescently 
labelled liposomal suspension in human urine was incorporated into MB49 cells and these cells were 
evaluated using flow cytometry. The surface functionalisation of the cationic liposomes with PEG 
ensures that the drug carrier is taken up into MB49 murine cells uniformly. Surprisingly, 2 or 5 mol% 
Chol-PEG functionalized Cat-LPs were taken up into the cells more efficiently compared to 
unmodified and other PEG modified liposomes. This result was in contrast to their stability 
behaviour in human urine as more rigid conformation of Chol-PEG based carrier supported their 
uptake into MB49 cells (Nakamura et al., 2017). Thus lipid based carriers incorporating both DSPE 
and Chol-PEG may be formulated for improved stability in human urine as well as cellular uptake 
into cancerous urothelial tissues. 
GuhaSarkar et al explored paclitaxel loaded composite liposomes in gellan hydrogel (PTX-LP-Gel) for 
intravesical delivery. Paclitaxel was encapsulated efficiently into the drug carrier (91.2 ± 0.7%) 
because of the affinity of the hydrophobic drug towards lipid bilayers. Apart from being 
mucoadhesive, gellan is a temperature- and ion-responsive polysaccharide, so it becomes physically 
cross-linked in the presence of urine, resulting in prolonged retention of the drug carrier onto the 
urothelial surface. 0.1% gellan was identified as the optimum concentration for syringeability 
through the catheter.  The liposomal component (124 nm, PDI 0.22, surface charge -16.8 mV) 
enhances urothelial cell permeation as a result of merging with the lipid content of the cell 
membranes. Based on cryo-TEM results, the size of the drug loaded liposome was increased with 
paclitaxel encapsulation to ~ 200 nm. PTX-LP-Gel exhibited a sustained drug release profile over 50 h 
(17.8 ± 3.0% of loaded drug) due to the smart matrix of the hydrogel; though porous structure 
facilitates controlled drug and / or liposome diffusion out of the hydrogel. Cellular uptake studies 
using CLSM confirmed superior NBT-II and T24 cell internalization of loaded rhodamine-6G, relative 
to the control cell group. Also, cytotoxic testing of the novel drug carrier using NBT-II and T24 cell 
lines suggested that they retained their cytotoxic effect with IC50 values of  55.7 ± 13.0 nm and 1.9 ± 
0.5 µm, respectively. LP-Gel was not detected in non-target organs during in vivo retention studies 
and the amount detected in the rat bladder 7 days post instillation was remarkably greater than that 
of the commercial product, Taxol (1.71 ± 0.86 µg/g vs. 0.02 ± 0.01 µg/g). The safety of LP-gel was 
confirmed based on scanning electron and atomic force microscopic images depicting intact 
urothelium, with residence of the gel formulation for up to 24 h. This work revealed that the limited 
mucoadhesiveness associated with conventional liposomes can be overcome by incorporation of 
liposomes within gellan gel. Moreover, toxic effect of cross-linkers (such as glutaraldehyde and 1-
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ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride) used with mucoadhesive polymers, to 
improve mucoadhesiveness of liposomes, will be avoided (GuhaSarkar et al., 2017). Overall, this 
work generated safe, injectable, mucoadhesive, ion-triggered in situ gelling carrier, resistant to pH 
changes in the bladder with a sustained release profile. 
5.3 In vitro - in vivo models to study intravesical drug delivery 
Various in vitro and in vivo models have been used to study drug delivery systems intended for 
intravesical administration. Different types of BC cells have been employed for cell viability studies. 
Murine sources include MBT-2 (Tamura et al., 2015), MB49 (Nakamura et al., 2017) and NBT-II 
(GuhaSarkar et al., 2017),  while T-24, RT-4, UM-UC-3,  5637 and HT-1376 are human cell lines 
(GuhaSarkar et al., 2017; Guo et al., 2016; Lu et al., 2015; Martin et al., 2014; Men et al., 2012; 
Neutsch et al., 2013; Zhang et al., 2014). They differ in terms of their invasive and metastatic 
tendencies. SV-HUC-1 are healthy bladder cell lines studied to evaluate the biocompatibility of drug 
carriers (Neutsch et al., 2013). These cells are often maintained in appropriate medium containing 
5% carbon dioxide at 37oC for optimal growth (Lu et al., 2015; Martin et al., 2014, 2013; Men et al., 
2012; Neutsch et al., 2013; Tamura et al., 2015; Zhang et al., 2014). 
During in vitro studies, cell viability in the presence of potential drug carriers was evaluated using 
different methods, such as bromodeoxyuridine and XTT assay (Neutsch et al., 2013), lactate 
dehydrogenase assay (Tamura et al., 2015), MTT assay (Guo et al., 2016; Lu et al., 2015; Men et al., 
2012; Zhang et al., 2014) and sulphorhodamine-B colorimetry (GuhaSarkar et al., 2017). The damage 
of the intravesical carriers to cell membrane was measured in terms of specific enzymes or 
antibodies release into the cytosol when carriers were mixed with malignant cells. Some researchers 
did not carry out in vitro cell viability or cytotoxicity testing of their formulations (Cook et al., 2015; 
Lin et al., 2014; Senyigiti et al.,2015). However, in vitro drug release (Cook et al., 2015; Senyigiti et 
al., 2015) and floating tendency (Lin et al., 2014) studies of their formulation in the presence of 
artificial urine were evaluated.  
There are detailed protocols available for the preparation of artificial urine for in vitro cell based 
studies, which is representative of the components of human urine but they are varied in 
composition and concentration of their constituents, which imparts on their pH (6.5-7.8), specific 
gravity (1.008-1.02 g/mL) and osmolality value (430-861 mOsm/kg) (Brooks and Keevil, 1997; Brown 
et al., 1989; Christmas et al., 2002; Chutipongtanate and Thongboonkerd, 2010; Grases and Llobera, 
1998; Mayrovitz and Sims, 2001; Opalko et al., 1997). Examples of constituents include urea, uric 
acid, creatinine, trisodium citrate, sodium chloride, potassium chloride, ammonium chloride, calcium 
chloride dehydrate, magnesium sulphate heptahydrate, sodium bicarbonate, disodium oxalate, 
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sodium sulphate, sodium dihydrogen phosphate and disodium hydrogen phosphate (Brooks and 
Keevil, 1997; Brown et al., 1989; Christmas et al., 2002; Grases and Llobera, 1998; Mayrovitz and 
Sims, 2001; Opalko et al., 1997). The artificial urine with pH, specific gravity and osmolality of 6.2, 
1.01 g/mL and 446 mOsm/kg, respectively, was appropriate for various biomedical applications 
(Chutipongtanate and Thongboonkerd, 2010).  
Martin et al evaluated the uptake of fluorescent carriers suspended in artificial urine into healthy 
human ureter using ex vivo binding assay (Martin et al., 2013). The in vitro cytotoxicity of free drug, 
blank nanoparticles, drug loaded modified and unmodified PLGA nanoparticles, on T-24 cells 
(metastatic, invasive high grade BC), RT-4 cells (papillary, well differentiated, non-invasive) and UM-
UC-3 cells (highly metastatic) were studied using WST-1 reagent and IC50 values determined (Martin 
et al., 2013). These values may help to establish the dose of formulation that would be toxic to 
urothelial cells.  
During in vivo studies, mice were induced with human bladder cancer (orthotopic model) by 
transurethral implantation (Tamura et al., 2015) or subcutaneous injection (Martin et al., 2014, 
2013) of BC cells like UM-UC-3 cells as well as by oral intake of water containing 0.05% (w/v) N-butyl-
N-(4-hydroxybutyl)-nitrosamine for 20 weeks (Guo et al., 2016). Predetermined concentration of 
carriers were instilled and the degree of tumor regression determined from the weight of bladder 
tumor after sacrificing mice (Martin et al., 2014, 2013; Tamura et al., 2015). The actual drug taken up 
may be evaluated based on LC-MS/MS analysis of extracts from bladder tumor homogenate (Tamura 
et al., 2015). Other authors  quantified in vivo retention of drug carriers in terms of observable 
fluorescence using fluorescence microscopy (Lu et al., 2015; Martin et al., 2014; Neutsch et al., 2013) 
or acid-fast staining and / or HE staining (Zhang et al., 2013). Men et al (Men et al., 2012) also used 
mice but did not test the antitumor efficacy by induction of bladder cancer. They simply tested the 
drug uptake into bladder tissues from the delivery system as well as its resistance to urine wash-out. 
Nevertheless, they evaluated the cytotoxic effects of free deguelin, drug nanoparticles and drug 
loaded hydrogel-nanoparticle composite formulations on T-24 cells while the anti-angiogenic 
potential of deguelin was assessed using transgenic zebrafish model (Men et al., 2012). 
Similar number (six) of injections were administered to mice and rats based malignant models but 
dose and dosing interval of the drug carriers differ probably due to pharmacological profile of 
various chemotherapeutic agents used (Martin et al., 2013; Tamura et al., 2015; Zhang et al., 2013). 
Therefore, it would be difficult to compare degree of tumor regression across studies. Moreover, 
some studies were less detailed in terms of the original volume of tumor (Tamura et al., 2015). Thus 
it is not easy to ascertain the degree of tumor regression by the final volume of tumor observed. 
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Wistar rats are typically used for in vivo studies, so Lin et al used these rats to assess the urine wash-
off resistance and sustained release profile of Poloxamer-based floating  and non-floating carriers 
(Lin et al., 2014). Zhang et al (Zhang et al., 2013) used similar rats to evaluate urothelial cellular 
uptake of chitosan/ß-GP/ Fe3O4-magnetic hydrogel-nanoparticles system. The immunological 
response of rat bladder to the intravesical instillation of BCG-based carriers was quantified by 
urinary analysis of cytokines and tissue histochemical analysis of CD4+ T cells (Zhang et al., 2013). 
GuhaSarkar’s group evaluated the in vivo retention of rhodamine and paclitaxel loaded liposomes 
and liposome-gel systems using healthy female and male rats (GuhaSarkar et al., 2017). However, 
the antitumor effect of the drug loaded formulations was not investigated in rats, in addition to their 
retention in the bladder. 
On the other hand, in vivo testing of formulations was not carried out in some studies reported 
(Cook et al., 2015; Lu et al., 2015; Neutsch et al., 2013; Senyigiti et al., 2015; Zhang et al., 2014). 
However, ex vivo mucoadhesive studies of some formulations were conducted using porcine (Cook 
et al., 2015; Lu et al., 2015; Zhang et al., 2014) or bovine (Senyigiti et al., 2015) bladder tissues. 
However, they quantified the mucoadhesiveness of their drug carriers differently using confocal 
laser-scanning microscope(Lu et al., 2015; Zhang et al., 2014), fluorescence stereomicroscope (Cook 
et al., 2015) and TA-XT Plus texture analyser (Senyigiti et al., 2015). 
5.4 Clinical trials  
TCGel®, a polymeric thermoresponsive hydrogel containing Pluronic F-127 (27%), PEG-400 (1.1%), 
HPMC (0.3%), double distilled water (71.6%) was developed by TheraCoat Ltd (Israel). It exhibited 
improved safety and residence within the bladder cavity between 6 to 8 hours and gradually 
eliminated during urine voiding, in comparison to simple mitomycin C solution during preclinical 
evaluation  (Zacchè et al., 2015). Thus it was assessed for intravesical application by mixing TCGel® 
with 40mg mitomycin C (standard dose prior to surgery) and pharmacological effect compared with 
same amount of mitomycin C mixed with water, in an ongoing trial for management of low risk 
recurrent NMIBC (TheraCoat Ltd., 2015).  
6 Conclusion 
The intravesical route is the most viable means of improving drug delivery for bladder cancer 
treatment, especially at the early stages, due to the limitations of oral and systemic routes. 
However, intravesical drug delivery  has disadvantages, like drug dilution by urine and drug wash-out 
during micturition when conventional formulations made of simple solution of the 
chemotherapeutic agent are used. Moreover, the urothelium limits permeation of potentially useful 
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therapeutic agents for BC treatment while carrying out its regulatory role. This results in frequent 
dosing or catheter retention within the urethral tract that leads to bladder irritation and infection.  
Drug carriers reviewed are of polymeric nature with potential to treat superficial BC and prevent 
disease progression to its metastatic and advanced forms.  Moreover, the composite 
nanoparticulate and in situ gelling formulations are able to combine benefits of both delivery 
systems to generate dosage forms, with improved safety, efficacy and sustained release profile. 
There are variations in the design of the in vitro and in vivo studies as well as evaluation of data 
generated from such studies. Some studies were not detailed enough to allow for comparison of 
cytotoxic or mucoadhesive profiles. Also, some authors did not carry out particular in vitro and ex 
vivo studies conducted by others, making it difficult to establish dosage regimen for such 
formulations. 
The issue of formulation design (modulation of formulation properties to generate uniform thin gel 
layer in situ, adequate strength and sustained drug release) for higher capacity of human bladder, 
identified by GuhaSarkar et al (GuhaSarkar and Banerjee, 2010) still persist. This has prevented 
promising formulations from being tested in human bladder during clinical trials. However, their 
findings have suggested that solubilisation of drugs in amphiphilic systems; surface modification of 
particulate systems and incorporation of such particulate systems into in situ gelling formulations 
would generate advanced carriers with superior drug loading, safety, in situ gelling, mucoadhesive / 
floating and selective bladder cancer cell penetrating features that would improve the cytotoxic 
profile of the incorporated therapeutics. Drug carriers that would explore combination of delivery 
strategies would be desirable in order to prevent BC recurrence and progression.  
Promising safety and cytotoxicity data generated from some of the studies offer hope that single 
drug loaded carriers may be investigated instead of multiple drugs based delivery systems widely 
explored in ongoing clinical trials for bladder cancer treatment. The harmonisation of the acceptable 
and realistic protocols for in vitro and in vivo models for studying intravesical delivery may accelerate 
the translation of some of the formulations, currently being developed, into the clinic. Therapeutic 
outcomes of patients would also be improved with promising disease prognosis. 
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